The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and ...

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

SMALL heart size is linked to higher mortality risk in individuals with normal ejection fraction , particularly in women and those with high-normal ejection fraction.

Both incident and recurrent heart failure hospitalization risk is associated with post-traumatic stress disorder among patients with CAD.

Cellipont Bioservices and Secretome Therapeutics are set to enter a collaboration in the manufacture of the latter’s cellular therapy, STM-01. The collaboration will see Cellipont offering technology ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Tom Nolan reviews this week’s research Exercise for 30 minutes three times a week on an exercise bike for a month; then make the sessions an hour long and add resistance training with two sets of ...

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...

Ms. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data ...